MARKET

AKTX

AKTX

Akari Therapeutics Plc
NASDAQ
0.2890
+0.0215
+8.04%
After Hours: 0.2721 -0.0169 -5.85% 17:56 12/31 EST
OPEN
0.2540
PREV CLOSE
0.2675
HIGH
0.2900
LOW
0.2509
VOLUME
835.95K
TURNOVER
--
52 WEEK HIGH
1.730
52 WEEK LOW
0.2178
MARKET CAP
13.23M
P/E (TTM)
-0.4932
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 12/31/2025 12:06
Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Benzinga · 12/31/2025 11:14
Akari Therapeutics CEO says company ‘progressing to critical inflection points’
TipRanks · 12/30/2025 14:20
Akari Therapeutics Partners with WuXi XDC to Advance ADC Candidate Toward Clinical Trials
Reuters · 12/30/2025 14:15
Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
Barchart · 12/30/2025 08:15
Weekly Report: what happened at AKTX last week (1222-1226)?
Weekly Report · 12/29/2025 10:30
Akari Advances Towards First-in-Human Trial With Novel ADC Payload
NASDAQ · 12/24/2025 07:34
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 12/23/2025 21:05
More
About AKTX
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.

Webull offers Akari Therapeutics PLC (ADR) stock information, including NASDAQ: AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.